|Alexander "Bo" Cumbo|
Stanton PR & Marketing represents the syndicate of high-powered life sciences investors that created AavantiBio, a gene therapy company focused on patients with rare genetic disorders.
Bain Capital Life Sciences, Perceptive Advisors, RA Capital Management and Sarepta Therapeutics put together $107M in Series A financing to launch AavantiBio.
Alexander “Bo” Cumbo, who served as chief commercial officer and executive VP at Sarepta, will helm AavantiBio, which is headquartered in the Boston area.
“Bo Cumbo has built a first-in-class rare disease commercial organization and has made tremendous contributions to Sarepta," said Doug Ingram, CEO. “We look forward to continuing to work with Bo as he builds a strong AavantiBio team and advances therapies to treat FA and other rare diseases.”
Stanton’s Scott Lessne handles AavantiBio.
No comments have been submitted for this story yet.